Novo Nordisk cuts its 2026 adjusted sales forecast to a decline of up to 6%, disappointing investors despite strong Q2 results.
Novo Nordisk shares slid over 5% after the company revised its 2026 guidance, projecting adjusted sales to decline 6% to flat at constant exchange rates. The updated outlook is below its prior forecast of a 4% to 12% drop, signaling softer demand expectations for its GLP-1 drugs, including Wegovy and Ozempic.
Second-quarter sales reached 78.49 billion kroner ($12.09 billion), up 3% in constant currency, while adjusted operating profit rose 11% to 33.39 billion kroner. The company also reported 5 million prescriptions for its Wegovy pill since its January launch, highlighting recent product expansions.
The guidance revision overshadowed strong quarterly performance, with investors focusing on the more cautious long-term outlook. Rival Eli Lilly is set to report earnings Wednesday, adding pressure to Novo Nordisk’s market position.